Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kuvan in children under 4 years with phenylketonuria
NL-OMON36625Phase 3Active, not recruiting
- Sponsor
- Merck Serono
- Start
- Jun 2011
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sapropterin in phenylketonuria (PKU) (2 arms), sponsored by Merck Serono. Primary endpoints: Dietary phenylalanine tolerance at 26 weeks, Safety at 26 weeks and 1 more. Started Jun 2011; status: active, not recruiting.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NL-OMON36625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36625.